JP2025503493A5 - - Google Patents

Info

Publication number
JP2025503493A5
JP2025503493A5 JP2024538092A JP2024538092A JP2025503493A5 JP 2025503493 A5 JP2025503493 A5 JP 2025503493A5 JP 2024538092 A JP2024538092 A JP 2024538092A JP 2024538092 A JP2024538092 A JP 2024538092A JP 2025503493 A5 JP2025503493 A5 JP 2025503493A5
Authority
JP
Japan
Prior art keywords
sequence
variable region
chain variable
cancer
ror1 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503493A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/142644 external-priority patent/WO2023125619A1/zh
Publication of JP2025503493A publication Critical patent/JP2025503493A/ja
Publication of JP2025503493A5 publication Critical patent/JP2025503493A5/ja
Pending legal-status Critical Current

Links

JP2024538092A 2021-12-28 2022-12-28 抗ror1抗体と抗ror1抗体薬物複合体及びその医薬的使用 Pending JP2025503493A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202111623091.0 2021-12-28
CN202111623091 2021-12-28
CN202210230033 2022-03-10
CN202210230033.X 2022-03-10
PCT/CN2022/142644 WO2023125619A1 (zh) 2021-12-28 2022-12-28 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途

Publications (2)

Publication Number Publication Date
JP2025503493A JP2025503493A (ja) 2025-02-04
JP2025503493A5 true JP2025503493A5 (cg-RX-API-DMAC7.html) 2026-01-13

Family

ID=86997955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538092A Pending JP2025503493A (ja) 2021-12-28 2022-12-28 抗ror1抗体と抗ror1抗体薬物複合体及びその医薬的使用

Country Status (8)

Country Link
US (1) US20250121081A1 (cg-RX-API-DMAC7.html)
EP (1) EP4458850A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503493A (cg-RX-API-DMAC7.html)
KR (1) KR20240125944A (cg-RX-API-DMAC7.html)
CN (1) CN118302448A (cg-RX-API-DMAC7.html)
CA (1) CA3242972A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330619A (cg-RX-API-DMAC7.html)
WO (1) WO2023125619A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN118496347B (zh) * 2024-05-30 2024-10-25 北京航空航天大学杭州创新研究院 一种用于抗体寡核苷酸偶联的方法
WO2026077395A1 (zh) * 2024-10-10 2026-04-16 杭州博之锐生物制药有限公司 抗ror1抗体药物-偶联物的联合用药
WO2026077394A1 (zh) * 2024-10-10 2026-04-16 杭州博之锐生物制药有限公司 一种抗ror1抗体-药物偶联物的药物组合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20160208018A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
US20200338210A1 (en) * 2016-12-22 2020-10-29 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
TWI804499B (zh) * 2017-06-23 2023-06-11 美商維洛斯生物公司 Ror1抗體免疫接合物
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
UA130338C2 (uk) 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
CN114829402B (zh) * 2019-09-27 2024-11-05 南京艾美斐生物医药科技有限公司 抗ror1抗体及其制备方法与应用
EP4241789A4 (en) * 2020-12-08 2025-04-02 Nona Biosciences (Shanghai) Co., Ltd. Protein-drug conjugate and site-specific conjugation method

Similar Documents

Publication Publication Date Title
JP2024544520A5 (cg-RX-API-DMAC7.html)
CN106459089B (zh) 生物素变体、链霉亲和素突变体以及它们的应用
JP2023510905A5 (cg-RX-API-DMAC7.html)
JP2019536740A5 (cg-RX-API-DMAC7.html)
JP2023547323A5 (cg-RX-API-DMAC7.html)
CN112566942A (zh) 用于制造抗体-药物缀合物的有效方法
JP2013056885A5 (cg-RX-API-DMAC7.html)
JP2004529963A5 (cg-RX-API-DMAC7.html)
JP2016503295A5 (cg-RX-API-DMAC7.html)
JP2023515941A5 (cg-RX-API-DMAC7.html)
WO2016033324A1 (en) Internalizing moieties for treatment of cancer
EP2315781A2 (fr) Antagonistes specifiques du recepteur fgf-r4
JP2019511201A5 (cg-RX-API-DMAC7.html)
JP2023519261A5 (cg-RX-API-DMAC7.html)
TWI726217B (zh) 含有抗globo h抗體之抗體-藥物共軛物及其用途
RU2765878C2 (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
JP2021523100A5 (cg-RX-API-DMAC7.html)
RU2019118653A (ru) НОВЫЙ Fab-ФРАГМЕНТ АНТИТЕЛА ПРОТИВ MUC1 ЧЕЛОВЕКА
TW201920273A (zh) 新穎的抗人類CEACAM5抗體Fab片段
JP2018528759A5 (cg-RX-API-DMAC7.html)
CN115335400A (zh) 结合整合素avb8的抗体及其用途
NL2020121B1 (en) Platinum-based functional moieties for preparing cell targeting conjugates
CN117327182A (zh) Cldn18.2单域抗体探针的制备方法及应用
JP2019532015A (ja) 環状ペプチドを含むワクチン組成物、環状ペプチドに対する抗体又はそれを含む抗癌組成物
WO2024199111A1 (zh) 靶向adam9的人源化抗体、其抗体药物偶联物及其应用